Nephros Inc. (NASDAQ:NEPH - Get Free Report) dropped 14.2% during mid-day trading on Monday . The company traded as low as $3.90 and last traded at $4.29. Approximately 143,052 shares traded hands during trading, an increase of 768% from the average daily volume of 16,484 shares. The stock had previously closed at $5.00.
Nephros Trading Down 14.2%
The business has a 50 day moving average of $2.66 and a 200-day moving average of $1.97. The firm has a market capitalization of $45.47 million, a P/E ratio of 61.29 and a beta of 0.96.
Nephros (NASDAQ:NEPH - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported $0.05 earnings per share for the quarter. The company had revenue of $4.88 million during the quarter, compared to analysts' expectations of $3.67 million. Nephros had a net margin of 5.16% and a return on equity of 9.43%.
Hedge Funds Weigh In On Nephros
A hedge fund recently bought a new stake in Nephros stock. Topline Capital Management LLC bought a new stake in Nephros Inc. (NASDAQ:NEPH - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 419,887 shares of the company's stock, valued at approximately $617,000. Topline Capital Management LLC owned approximately 3.98% of Nephros at the end of the most recent quarter. Institutional investors own 41.10% of the company's stock.
Nephros Company Profile
(
Get Free Report)
Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nephros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nephros wasn't on the list.
While Nephros currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
